What's new

China Secures 100 Million Doses of BioNTech Vaccine

Dark1

BANNED
Joined
Feb 29, 2020
Messages
1,780
Reaction score
-33
Country
India
Location
India
"A Chinese drugmaker has secured 100 million doses of the coronavirus vaccine co-developed by Pfizer Inc. and BioNTech SE, as the country seeks overseas shots in addition to home-made ones to ensure immunization for the world’s most populous nation.
Shanghai Fosun Pharmaceutical Group Co., which in March made an agreement with BioNTech to develop and market the mRNA shot in China, will make an advance payment of 250 million euros ($300 million) for an initial 50 million doses. The German vaccine maker will supply no fewer than 100 million doses for China by the end of 2021, Fosun said in a statement filed with the Hong Kong Stock Exchange Wednesday."

I had no idea. Thought this requires a seperate thread.
@MilSpec @bahadur

Discuss.
 
Old news...
The vaccine BNT162b2 is a collaboration of fosun pharma & bioNtech.Phase 2 trial conducted in china back in 2020,Fosun has invested $135 million + on the vac development and owns equity ,the vaccine is manufactured in China.
 
Last edited:
This is old news.Because Shanghai Fuxing Medicine is the sole agent and co-developerof Pfizer Inc. And BioNTech SE in Greater China Region.
2020.11.13, the China Food and Drug Administration approved the Fosun MRNA II clinical trial.
2020.12.17,China's Food and Drug Administration approved Fosun's application to use 100 million vaccines in 2021.
Screenshot_20210123_112210.jpg

I guess the more vaccine we have, the better,Could end up stockpiling twice as much vaccine as the population.
Earlier, Chinese epidemic prevention experts said that at present, some vaccines in the United States, China will have them simultaneously, and some vaccines in China will also be available in the United States. China and the United States, Europe in the vaccine above the deep intersection. The Chinese market will have all the vaccines, and the production capacity of a single vaccine can not meet the needs. It is estimated that the United States will eventually stockpile 1 billion vaccines and China will need 2-3 billion vaccines.
 
Old news...
The vaccine BNT162b2 is a collaboration of fosun pharma & bioNtech.Phase 2 trial conducted in china back in March2020,Fosun has invested $135 million + on the vac development and owns equity ,the vaccine is manufactured in China.

I’m accustomed to Indians lying on PDF but an Indian lying to save Chinese honor..now that is a first :lol:

It isn’t a ‘collaboration’ there is no plant in China just yet , a Chinese plant is being negotiated.

The intellectual property for the BNT162b2 is jointly owned by BioNTech Germany and Pfizer.
Meanwhile China is importing a 100 million doses from Pfizer/BioNTech.

Pfizer COVID-19 Collaboration

On April 9, 2020, we announced that we and Pfizer had entered into a collaboration agreement to co-develop our potential first-in-class COVID-19 mRNA vaccine program, BNT162, aimed at preventing COVID-19. Under the terms of the agreement, Pfizer agreed to pay us $185 million in upfront payments, including an equity investment of €103.9 million ($113 million, translated using the exchange rate then in effect as published by the German Central Bank (Deutsche Bundesbank)), which was received in late April 2020, and a cash payment of €65.5 million ($72 million, translated using the exchange rate then in effect as published by the German Central Bank (Deutsche Bundesbank)), which was received in May 2020. The issuance of 2,377,446 ordinary shares with the nominal amount of €2,377,446 was registered within the commercial register (Handelsregister) as of May 5, 2020. We are eligible to receive future milestone payments of up to $563 million for potential aggregate consideration of $748 million. Pfizer and we will share development costs equally. Initially, Pfizer will fund 100% of the development costs, and we will repay Pfizer our 50% share of these costs if success-based milestones are reached, or with proceeds generated from the commercialization of the vaccine, if approved. If the vaccine program is not successful or does not generate sufficient proceeds, we will not be required to pay back our 50% share of the development costs incurred.

 
Back in March 2020, I guess only China feels the urgent need to find an effective vaccine. That's why Fosun invested in BioNTech for the development of a mRNA vaccine.

Fosun invest US$135 million for 1.58 million shares in BioNTech and the future development and marketing rights of BioNTech vaccine in China, Hong Kong, Macau and Taiwan.

BioNTech later partner with Pfizer for the rest of the world.
 
I’m accustomed to Indians lying on PDF but an Indian lying to save Chinese honor..now that is a first :lol:

It isn’t a ‘collaboration’ there is no plant in China just yet , a Chinese plant is being negotiated.

The intellectual property for the BNT162b2 is jointly owned by BioNTech Germany and Pfizer.
Meanwhile China is importing a 100 million doses from Pfizer/BioNTech.

Pfizer COVID-19 Collaboration

On April 9, 2020, we announced that we and Pfizer had entered into a collaboration agreement to co-develop our potential first-in-class COVID-19 mRNA vaccine program, BNT162, aimed at preventing COVID-19. Under the terms of the agreement, Pfizer agreed to pay us $185 million in upfront payments, including an equity investment of €103.9 million ($113 million, translated using the exchange rate then in effect as published by the German Central Bank (Deutsche Bundesbank)), which was received in late April 2020, and a cash payment of €65.5 million ($72 million, translated using the exchange rate then in effect as published by the German Central Bank (Deutsche Bundesbank)), which was received in May 2020. The issuance of 2,377,446 ordinary shares with the nominal amount of €2,377,446 was registered within the commercial register (Handelsregister) as of May 5, 2020. We are eligible to receive future milestone payments of up to $563 million for potential aggregate consideration of $748 million. Pfizer and we will share development costs equally. Initially, Pfizer will fund 100% of the development costs, and we will repay Pfizer our 50% share of these costs if success-based milestones are reached, or with proceeds generated from the commercialization of the vaccine, if approved. If the vaccine program is not successful or does not generate sufficient proceeds, we will not be required to pay back our 50% share of the development costs incurred.

Such a messy attempt to discredit Fosun involvement imao..

Fosun-COVID-19 Collaboration

On March 13, 2020, we entered into a Development and License Agreement with Shanghai Fosun Pharmaceutical Industrial Development, Co., Ltd, or Fosun Pharma, for the development and commercialization in People’s Republic of China (including Hong Kong SAR, Macau SAR and Taiwan), or the Fosun Territory, of immunogenic compositions generated by BioNTech and comprising uridine RNA, modified RNA and/or replicon technology for prophylaxis against SARS-CoV-2 in humans. We refer to this agreement as the Fosun Agreement.



*1,580,777 ordinary shares issued to Fosun Pharma in connection with our collaboration with Fosun Pharma;​

Other than the gain from equity on the vac,Fosun will take 61-70% profit from that 100 million doses secured by china.


 

Attachments

  • 1611376020795.png
    1611376020795.png
    51.6 KB · Views: 42
Commonsense tells us, no nation on earth today can manufactured vaccines to the scale as China.
There is a global shortage of vaccines but a huge demand. The orders will be beyond 2021.
These Chinese businessman are obviously seizing the opportunity to make more money for their companies and these vaccines are intended for exports. :coffee:
 
Such a messy attempt to discredit Fosun involvement imao..

Fosun-COVID-19 Collaboration

On March 13, 2020, we entered into a Development and License Agreement with Shanghai Fosun Pharmaceutical Industrial Development, Co., Ltd, or Fosun Pharma, for the development and commercialization in People’s Republic of China (including Hong Kong SAR, Macau SAR and Taiwan), or the Fosun Territory, of immunogenic compositions generated by BioNTech and comprising uridine RNA, modified RNA and/or replicon technology for prophylaxis against SARS-CoV-2 in humans. We refer to this agreement as the Fosun Agreement.



*1,580,777 ordinary shares issued to Fosun Pharma in connection with our collaboration with Fosun Pharma;​

Other than the gain from equity on the vac,Fosun will take 61-70% profit from that 100 million doses secured by china.



stop lying, development implies pursuing clinical trials Phase 1 to 3 and obtaining regulatory approval in China. Fosun had no part in engineering the vaccine. The mRNA platform IP belongs exclusively to BioNTech, the IP for the BNT162 vaccine is jointly held by Pfizer and BioNTech .

This is from the BioNTech website so take your lies elsewhere.

  • BioNTech and Fosun Pharma will jointly conduct clinical trials of BNT162 in China, leveraging BioNTech’s proprietary mRNA vaccine technology and Fosun Pharma’s clinical development and commercialization capabilities in China
  • Fosun Pharma will commercialize the vaccine in China upon regulatory approval, with BioNTech retaining full rights to develop and commercialize the vaccine in the rest of the world
  • Fosun Pharma will pay BioNTech up to USD 135M (EUR 120M) in upfront and potential future investment and milestone payments; the two companies will share future gross profits from the sale of the vaccine in China
 
So much investment for a failed vaccine, as per the han experts here.
With the usa being so openly antagonistic to China, china should have some self respect and reject this failed western vaccine.
I knew that eventually the Chinese government would use the western vaccines and the Chinese vaccines would be reserved for the general public and the poorer countries friendly to the Chinese communists.
Rest all is a eyewash.
 
stop lying, development implies pursuing clinical trials Phase 1 to 3 and obtaining regulatory approval in China. Fosun had no part in engineering the vaccine. The mRNA platform IP belongs exclusively to BioNTech, the IP for the BNT162 vaccine is jointly held by Pfizer and BioNTech .

This is from the BioNTech website so take your lies elsewhere.

  • BioNTech and Fosun Pharma will jointly conduct clinical trials of BNT162 in China, leveraging BioNTech’s proprietary mRNA vaccine technology and Fosun Pharma’s clinical development and commercialization capabilities in China
  • Fosun Pharma will commercialize the vaccine in China upon regulatory approval, with BioNTech retaining full rights to develop and commercialize the vaccine in the rest of the world
  • Fosun Pharma will pay BioNTech up to USD 135M (EUR 120M) in upfront and potential future investment and milestone payments; the two companies will share future gross profits from the sale of the vaccine in China

Development implies pursuing clinical trials Phase 1 to 3 and obtaining regulatory approval in China. Fosun had no part in engineering the vaccine.
This is a direct quote from BioNtech official statement ;

On March 13, 2020, Fosun Pharma became the strategic partner of BioNTech in China, jointly developing and commercializing vaccine products for COVID-19 based on its proprietary mRNA technology platform in Mainland China, Hong Kong and Macau Special Administration Region and the Taiwan Region. Since the collaboration between the two sides, Fosun Pharma has been deeply involved in the research and development of mRNA vaccines. In addition to comprehensively and deeply discussing the research and development plans with partners and completing clinical trials in China, Fosun Pharma has also designed and completed animal challenge trials of selected mRNA vaccines, including BNT162b2, in collaboration with Chinese research institutes, and shared outcomes with partners in a timely manner.

Everythinmg I said is based upon the fosun agreement signed by BioNTech. China's Fosun gets to keep a hefty 70-61 % profit as per the Fosun Agreement, from the 100 m doses if china agrees to allow the vac in china.
 
Last edited:
Commonsense tells us, no nation on earth today can manufactured vaccines to the scale as China.
There is a global shortage of vaccines but a huge demand. The orders will be beyond 2021.
These Chinese businessman are obviously seizing the opportunity to make more money for their companies and these vaccines are intended for exports. :coffee:

reality tells us the largest producer of vaccines today is India. Meanwhile the Swiss are about to make a million doses of vaccine a day in just one Lonza plant in Switzerland peak global production will hit a billion doses.

reality also tells us inactivated (Chinese] vaccines cannot be produced at the same rate as mRNA vaccines.
Mainly because mRNA is chemically synthesized while inactivated vaccines are grown organically on pig fat and chemically inactivated - a slow process prone to quality control issues.
 
Commonsense tells us, no nation on earth today can manufactured vaccines to the scale as China.
There is a global shortage of vaccines but a huge demand. The orders will be beyond 2021.
These Chinese businessman are obviously seizing the opportunity to make more money for their companies and these vaccines are intended for exports. :coffee:

It Appears Common Sense is not so common.


The Serum Institute of India is the world’s largest manufacturer of vaccines by volume, founded over 50 years ago by now-multibillionaire Cyrus Poonawalla. It will likely provide not only almost all the vaccines administered in India, but many elsewhere in the world too, once exports are permitted later in the year.
 
This is a direct quote from BioNtech official statement ;

On March 13, 2020, Fosun Pharma became the strategic partner of BioNTech in China, jointly developing and commercializing vaccine products for COVID-19 based on its proprietary mRNA technology platform in Mainland China, Hong Kong and Macau Special Administration Region and the Taiwan Region. Since the collaboration between the two sides, Fosun Pharma has been deeply involved in the research and development of mRNA vaccines. In addition to comprehensively and deeply discussing the research and development plans with partners and completing clinical trials in China, Fosun Pharma has also designed and completed animal challenge trials of selected mRNA vaccines, including BNT162b2, in collaboration with Chinese research institutes, and shared outcomes with partners in a timely manner.

Fosun Pharma has been deeply involved in the research and development of mRNA vaccines. This statement is from the Fosun website and not BioNTech.

Fosun has developed its own mRNA technology in-house mostly related to treatment of Cancer NOT COVID. The above statement implies Fosun has in-house mRNA development experience.

However, it’s role in BNT162b2 is limited to local clinical trails and license production for the Chinese market. The IP for the mRNA vehicle for the BNT162b2 belongs exclusively to BioNTech. The IP and production rights for BNT162b2 vaccine is jointly held by Pfizer and BioNTech outside China.
 
Fosun Pharma has been deeply involved in the research and development of mRNA vaccines. This statement is from the Fosun website and not BioNTech.

Fosun has developed its own mRNA technology in-house mostly related to treatment of Cancer NOT COVID. The above statement implies Fosun has in-house mRNA development experience.

However, it’s role in BNT162b2 is limited to local clinical trails and license production for the Chinese market. The IP for the mRNA vehicle for the BNT162b2 belongs exclusively to BioNTech. The IP and production rights for BNT162b2 vaccine is jointly held by Pfizer and BioNTech outside China.
Does this look like Fosun official website to you?

BTW nobody's talking about Ip ,since Fosun invested in BioNtech,not the other way around,BioNtech is likely the parent here,but contrary to what you tried to insinuate,Fosun invested 135 million + in the development of vac ,and obtained 1,580,777 equity shares , the agreement makes it clear that fosun will get 70-61 % of profit from BioNtech vaccines ever sold to CHINA,Taiwan,HK,Macau. That is, if Chinese Health Ministry even allows the Mrna vac in china,which haven't happened yet.
 
It Appears Common Sense is not so common.

Overheard: this Indian electrician telling his angry lady client.
Commonsense is a rare gift of God and what is so strange if I don't have any.
True and in India it is even rarer.

:sarcastic: :sarcastic: :sarcastic:
So it is not necessary for you to explain or defend yourself.
We understand.
 

Pakistan Defence Latest Posts

Pakistan Affairs Latest Posts

Back
Top Bottom